The Switzerland market ended higher on Friday, extending gains to a third straight session, as encouraging European and U.S. economic data and optimism about interest rate cuts helped underpin sentiment. With the KOF Economic Barometer rising to 101.6 in August 2024, up from a revised 100.6 in July, investors are keenly watching high growth tech stocks that can capitalize on this positive economic outlook and robust market sentiment.
Top 10 High Growth Tech Companies In Switzerland
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| LEM Holding | 9.25% | 18.37% | ★★★★☆☆ |
| Santhera Pharmaceuticals Holding | 22.30% | 32.48% | ★★★★★★ |
| Temenos | 7.59% | 14.32% | ★★★★☆☆ |
| SoftwareONE Holding | 8.67% | 52.28% | ★★★★★☆ |
| Comet Holding | 19.03% | 48.25% | ★★★★★☆ |
| Cicor Technologies | 7.10% | 27.73% | ★★★★☆☆ |
| Basilea Pharmaceutica | 8.99% | 36.39% | ★★★★★☆ |
| Kudelski | 9.93% | 120.15% | ★★★★☆☆ |
| Sensirion Holding | 13.96% | 104.68% | ★★★★☆☆ |
| MCH Group | 5.18% | 83.82% | ★★★★☆☆ |
Let’s explore several standout options from the results in the screener.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Basilea Pharmaceutica AG is a commercial-stage biopharmaceutical company specializing in developing products for oncology and anti-infectives, with a market cap of CHF557.57 million.
Operations: The company’s primary revenue stream is derived from the discovery, development, and commercialization of innovative pharmaceutical products, generating CHF149.02 million. The focus areas include oncology and anti-infectives.
Basilea Pharmaceutica, headquartered in Allschwil, has recently seen the European Commission extend the indications of its antifungal Cresemba® to pediatric patients, triggering a CHF 10 million milestone payment from Pfizer. Despite reporting a revenue drop to CHF 76.29 million for H1 2024 and net income falling to CHF 20.74 million, Basilea’s R&D expenses reflect a strategic focus on innovation with significant investments in clinical studies. The company’s earnings are forecasted to grow by an impressive 36.39% annually and become profitable within three years, outpacing the Swiss market’s average growth rate of 4.4%.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Comet Holding AG, along with its subsidiaries, offers X-ray and radio frequency (RF) power technology solutions across Europe, North America, Asia, and globally; the company has a market cap of CHF2.69 billion.
Operations: Comet Holding AG generates revenue primarily through its three segments: X-Ray Systems (CHF115.34 million), Industrial X-Ray Modules (CHF95.90 million), and Plasma Control Technologies (CHF180.62 million). The company operates globally, providing advanced technology solutions in the fields of X-ray and RF power.
Comet Holding AG, a Swiss tech firm, reported half-year sales of CHF 189.32 million and net income of CHF 4.06 million, reflecting a substantial increase from the previous year’s CHF 1.94 million. Despite a volatile share price over the past three months, Comet’s earnings are expected to grow significantly at 48.3% annually over the next three years, outpacing the Swiss market’s average growth rate of 11.8%. Notably, R&D expenses have been pivotal; with investments driving innovation in their semiconductor and X-ray technology segments which serve high-profile clients like TSMC and Apple.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: LEM Holding SA, along with its subsidiaries, offers solutions for measuring electrical parameters across various regions including China, Japan, South Korea, India, Southeast Asia, Europe, the Middle East, Africa, NAFTA and Latin America and has a market cap of CHF1.42 billion.
Operations: LEM Holding SA specializes in providing electrical parameter measurement solutions globally. The company generates its revenue primarily through sales of these measurement solutions across diverse regions, leveraging its expertise to cater to various markets.
LEM Holding, a Swiss tech firm, has seen its earnings forecast to grow at 18.4% annually, surpassing the Swiss market’s average of 11.8%. Despite a recent dip in first-quarter sales to CHF 80.96 million from CHF 112.34 million last year, the company remains focused on innovation with R&D expenses contributing significantly to their growth strategy. Notably, LEM’s revenue is projected to increase by 9.2% per year, driven by advancements in their electronic components segment which serves high-profile clients globally.
Where To Now?
Interested In Other Possibilities?
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com